Market Overview

Stifel Lays Out The Bull Case For Intuitive Surgical

Related ISRG
Barclays Praises Impressive Q3 From Intuitive Surgical
The Market In 5 Minutes: Oil Inventories, Earnings Beats And A Walgreens-Rite Aid Snag

Stifel analyst Rick Wise released a note upgrading Intuitive Surgical (NASDAQ: ISRG) from Hold to Buy and assigned a price target of $600.

Wise believes that “the next leg of the ISRG story is starting to take shape” in response to the company’s recently released earnings report.

There are several factors that are leading to these beliefs: 1) Procedure volumes appear to be recovering, 2) New product launches, 3) Future product launches are coming, 4) Intuitive Surgical is expanding geographically, 5) Expansions in global sales and marketing organization.

Related Link: Apple Shares Up Slightly Following Q3 Earnings, Bank Of America Comments

While the second quarter appeared to be strong, Wise did denote that 2014 is a transition year with challenges still remaining. These include ongoing capital spending, uncertainties involving the product cycle and the benign gynecological surgical market.

Sales growth and earnings power is key to stock price appreciation. Wise speculates “over the next 3-5 years, ISRG sales can grow sustainably at a 10% or better pace, and that EPS can grow 15-20%.”

He believes that the stock is under-earning relative to the company’s normalized earning power. If the re-acceleration thesis proves correct, Wise expects the stock to have an above-average multiple and to reach its $600 price target.

Shares in the pre-market were trading up 12.71 percent at $442.00.

Latest Ratings for ISRG

Oct 2016Wells FargoInitiates Coverage OnOutperform
Aug 2016Raymond JamesInitiates Coverage onOutperform
Jul 2016BarclaysMaintainsOverweight

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Rick Wise Stifel NicolausAnalyst Color Upgrades Price Target Analyst Ratings


Related Articles (ISRG)

View Comments and Join the Discussion!